Company Description
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC.
The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020.
CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jan 25, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 142 |
| CEO | Arthur Kuan |
Contact Details
Address: 400 Spectrum Center Drive, Suite 2040 Irvine, California 92618 United States | |
| Phone | 949 409 3700 |
| Website | cgoncology.com |
Stock Details
| Ticker Symbol | CGON |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 1991792 |
| CUSIP Number | 156944100 |
| ISIN Number | US1569441009 |
| Employer ID | 37-1611499 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Arthur Kuan | Chairman and Chief Executive Officer |
| Ambaw Bellete M.S. | President and Chief Operating Officer |
| James M. DeTore | Interim Principal Financial and Accounting Officer |
| Swapnil Bhargava Ph.D. | Chief Technical Officer |
| Amy Steele | Vice President of Finance and Administration |
| Joshua F. Patterson | General Counsel, Chief Compliance Officer and Secretary |
| Sarah Connors | Vice President of Communications and Patient Advocacy |
| Bing Kung | Vice President of Corporate Development |
| Dr. Vijay Kasturi M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2026 | 10-K | Annual Report |
| Feb 27, 2026 | 8-K | Current Report |
| Jan 13, 2026 | 8-K | Current Report |
| Jan 13, 2026 | 424B5 | Filing |
| Jan 9, 2026 | 144 | Filing |
| Jan 9, 2026 | 8-K | Current Report |
| Nov 26, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 10-Q | Quarterly Report |